Sonoma Pharmaceuticals, Inc. (SNOA) stock prices were down 18.88% some time after market trading commenced on July 15th, 2021, bringing the price per share down to USD$6.23 early on in the trading day.
Partnership with EMC Pharma
March 26th, 2021 saw the company report having entered into a new partnership with EMC Pharma in light of it having gained exclusive rights for the U.S commercialization of prescription dermatology and prescription eye care products. The pharmaceutical company was also granted non-exclusive rights to sell their wound care products into government channels. The initial term of the agreement is subject to minimum purchases and is set for five years, with the option to renew.
Network of Partnerships
September 2020 saw the company launch two new products, Nasocyn Nasal Care and Oracyn Oral Care in collaboration with its partner, Te Arai Biofarma Ltd. December 2020 saw the company partner up with Gabriel Science, LLC in order to penetrate the dental markets in the U.S with their HOCI product. January 2021 saw the company receive clearances in Thailand, after which the sales of Dermodacyn disinfectant commenced in Hong Kong and Thailand, through its partner, VetSynova Co. Ltd.
Total Revenues for the quarter ended March 31st, 2021 came in at USD$2.2 million, down by USD$2.1 million as compared to the same time period of the prior year. The 50% reduction was largely driven by the USD$1.6 million decline in the U.S, which, in turn, was motivated by the decline of the company’s dermatology business. The dermatology business has since been partnered with EMC Pharma, LLC. Further compounding the year-over-year difference was USD$800,000 in revenue adjustments in relation to the overestimation of revenue in the prior-year quarter, having been determined using a look-back analysis.
As a result of the Invekra contract having concluded in October of 2020 resulted in a USD$0.7 million reduction in revenues generated from Latin America sales, further contributing to the yearly difference in total revenue. As per the contract, SNOA the company manufactured at low margins for Invekra. Since the conclusion of the contract, manufacturing has continued at reduced quantities but higher margins.
Future Outlook for SNOA
Armed with a network of partnerships secured over the past few quarters, SNOA is poised to capitalize on the chances afforded to it. The company is keen to continue its trajectory of success as it pushes for the consolidation and expansion of its market footprint around the globe. Current and potential investors are hopeful that management will be able to usher in sustained and significant increases in shareholder value.